clinic execut studi initi
messag report earn line investor
expect spoke management highlight continu execut
clinic develop pipelin enrol patient registr phase ii
kra lung cancer studi initi combin studi
keytruda erbitux inhibitor novn-sw compani
also report updat mo phase ii sitravatinib opdivo studi lung
cancer potenti increment read-through on-going phase sapphir
studi evalu doublet updat estim account result maintain buy
pt
despit execut clinic trial includ enrol
registr phase ii trial krystal kra nsclc
base combin studi believ benchmark single-arm single-ag
acceler approv kra nsclc orr month durat
well orr month durat combin studi
keytruda nsclc erbitux inhibitor novn-
sw nsclc on-going combin studi egfr inhibitor gilotrif
boehring inhibitor remain on-track initi
management highlight plan near-term data disclosur around
view evolut broader field kra inhibitor compani
remain on-track updat phase data expect report
addit nsclc patient includ patient least month follow-
expect complet enrol singl arm registration-en phase
ii trial potenti lead top-lin readout along
initi combin data keep within month singl agent phase ii
month combin see initi pipelin move
focu legaci busi slow initi coverag neutral rate
valuat rang respect accord compani also reiter
saw materi differ inhibitor potenti competitor
see initi krash cancer call so
 initi coverag buy pt dose lower
level novn reach monotherapi studi regard potenti competitor
data see guggenheim preview planner
given readout focu non-nsclc tumor expect regard singl
agent activ low given tumor biolog posit data view could
valid inhibit tumor type beyond nsclc limit downsid risk
beyond expect provid preclin updat kra inhibitor
updat phase ii sitravatinib data highlight numer higher mo rel prior
disclosur may increment posit phase sapphir trial recal
multikinas inhibitor sitravatinib opdivo undergo pivot phase trial
sapphir random docetaxel post-checkpoint inhibitor non-smal cell lung
cancer nsclc interim os analysi potenti around ye phase
ii studi previous read month mo earlier analysi
recent month mo month strictli set similar sapphir
potenti bode well docetaxel histor confer month mo
pretreat nsclc trial note result specif patient
prior clinic benefit inhibit expect constitut major
sapphir patient data studi last seen esmo see note
page analyst certif import disclosur
esmo field report sitravatinib updat esmo consist w/ prior data random
trial requir registr competitor updat phase
ib studi multi-tki cabometyx tecentriq rog-sw upcom
confer see note guggenheim preview planner sever
updat across biotech coverag buy strong quarter revenu
head multipl clinic mileston readout
updat estim account result maintain buy rate
pt end quarter cash invest increas
oper expens forecast account result
page analyst certif import disclosur
valu mirati use dcf base valuat method valuat base probability-adjust sitravatinib
opportun second-lin nsclc potenti indic sitravatinib along probability-adjust opportun
kra cancer pipelin agent repres upsid potenti valuat use discount rate consist
develop stage biotech compani coverag termin growth rate appli third year
risk valuat includ regulatori commerci setback potenti emerg new competitor
dilut financ beyond assum
page analyst certif import disclosur
total cost expens
interest incom net
loss extinguish debt
incom tax
guggenheim secur llc sec file
page analyst certif import disclosur
